Research programme: anticancer therapeutics - Genentech/Xenetic BiosciencesAlternative Names: Cancer compound - Genentech/Lipoxen
Latest Information Update: 17 Jun 2014
At a glance
- Originator Genentech; Lipoxen Technologies
- Developer Genentech; Xenetic Biosciences
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer